4.6 Letter

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms

Journal

HAEMATOLOGICA
Volume 103, Issue 1, Pages -

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2017.177600

Keywords

-

Categories

Funding

  1. Novartis Pharmaceuticals
  2. Cancer Center Support Grant/Core Grant [P30 CA008748]
  3. NCI [1K08CA188529-01, KK12CA087723-14, R01CA173636, K99 HL122503-01A1, F30CA18349]
  4. NIH National Institute of General Medical Sciences [T32 GM007739]
  5. NATIONAL CANCER INSTITUTE [R01CA173636, K12CA087723, K08CA188529, P30CA008748, F30CA183497] Funding Source: NIH RePORTER
  6. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K99HL122503] Funding Source: NIH RePORTER
  7. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available